Mantle Cell Lymphoma (MCL) Latest Advances
Find the Latest Research About Mantle Cell Lymphoma (MCL)
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5426 publications
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.
Journal: AME clinical trials review
Published: June 22, 2026
FDA Announces Efforts to Implement Real-Time Clinical Trial Reporting.
Journal: Cancer discovery
Published: June 17, 2026
The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.
Journal: Expert opinion on drug discovery
Published: June 15, 2026
Ibrutinib improves overall survival in patients with mantle cell lymphoma.
Journal: Nature reviews. Clinical oncology
Published: June 03, 2026
Orbital infiltration in relapsed mantle cell lymphoma.
Journal: Orbit (Amsterdam, Netherlands)
Published: June 02, 2026
Where next for BTKi-BCL2i combinations in mantle cell lymphoma?
Journal: British journal of haematology
Published: June 01, 2026
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma.
Journal: Studies in health technology and informatics
Published: May 23, 2026
First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.
Journal: Cancer discovery
Published: May 21, 2026
Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.
Journal: Journal of cellular and molecular medicine
Published: May 19, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.
Journal: Research square
Published: May 18, 2026
More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.
Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
Last Updated: 06/30/2026